JP2014503579A - プロセス - Google Patents
プロセス Download PDFInfo
- Publication number
- JP2014503579A JP2014503579A JP2013550951A JP2013550951A JP2014503579A JP 2014503579 A JP2014503579 A JP 2014503579A JP 2013550951 A JP2013550951 A JP 2013550951A JP 2013550951 A JP2013550951 A JP 2013550951A JP 2014503579 A JP2014503579 A JP 2014503579A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxypyrone
- iron
- aqueous solution
- ferric
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 91
- LIPRKYKMVQPYPG-UHFFFAOYSA-N 3-Hydroxy-2H-pyran-2-one Chemical compound OC1=CC=COC1=O LIPRKYKMVQPYPG-UHFFFAOYSA-N 0.000 claims abstract description 133
- 239000007864 aqueous solution Substances 0.000 claims abstract description 132
- -1 iron hydroxypyrone compound Chemical class 0.000 claims abstract description 90
- 150000002505 iron Chemical class 0.000 claims abstract description 74
- FBUKVWPVBMHYJY-UHFFFAOYSA-N noncarboxylic acid Natural products CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims abstract description 31
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical group CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 claims description 124
- 239000000243 solution Substances 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 78
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 72
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 claims description 60
- 229940043353 maltol Drugs 0.000 claims description 57
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 53
- QQTUBEKQMMRXHC-UHFFFAOYSA-N 3-hydroxypyran-2-one;iron Chemical compound [Fe].OC1=CC=COC1=O QQTUBEKQMMRXHC-UHFFFAOYSA-N 0.000 claims description 50
- 229910052742 iron Inorganic materials 0.000 claims description 35
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 34
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 34
- 239000002244 precipitate Substances 0.000 claims description 27
- 239000002585 base Substances 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 22
- VEYIMQVTPXPUHA-UHFFFAOYSA-N 3-hydroxypyran-4-one Chemical group OC1=COC=CC1=O VEYIMQVTPXPUHA-UHFFFAOYSA-N 0.000 claims description 20
- 235000014413 iron hydroxide Nutrition 0.000 claims description 20
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 16
- 229960002089 ferrous chloride Drugs 0.000 claims description 12
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 claims description 12
- FPTJMROABUHXFD-UHFFFAOYSA-N 3,4,5-trihydroxypyran-2-one Chemical compound OC1=COC(=O)C(O)=C1O FPTJMROABUHXFD-UHFFFAOYSA-N 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical group [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- YIKYNHJUKRTCJL-UHFFFAOYSA-N Ethyl maltol Chemical compound CCC=1OC=CC(=O)C=1O YIKYNHJUKRTCJL-UHFFFAOYSA-N 0.000 claims description 6
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 6
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 6
- WTLPSDOYWLDZSL-UHFFFAOYSA-N OC1=CC(=O)C=CO1 Chemical group OC1=CC(=O)C=CO1 WTLPSDOYWLDZSL-UHFFFAOYSA-N 0.000 claims description 5
- 208000007502 anemia Diseases 0.000 claims description 5
- 229940093503 ethyl maltol Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 150000007942 carboxylates Chemical class 0.000 claims description 4
- KEGLBJTZISWNID-UHFFFAOYSA-N iron;3,4,5-trihydroxypyran-2-one Chemical compound [Fe].OC1=COC(=O)C(O)=C1O KEGLBJTZISWNID-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- SFVUIBOQUATZDQ-UHFFFAOYSA-N 3,4-dihydroxypyran-2-one;iron Chemical compound [Fe].OC=1C=COC(=O)C=1O SFVUIBOQUATZDQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000011790 ferrous sulphate Substances 0.000 claims description 2
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 229940032296 ferric chloride Drugs 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000003446 ligand Substances 0.000 description 19
- 229960004887 ferric hydroxide Drugs 0.000 description 18
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 16
- 230000007935 neutral effect Effects 0.000 description 16
- 239000012670 alkaline solution Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- 241000894007 species Species 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- AHPWLYJHTFAWKI-UHFFFAOYSA-K iron(3+);2-methyl-4-oxopyran-3-olate Chemical compound [Fe+3].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-].CC=1OC=CC(=O)C=1[O-] AHPWLYJHTFAWKI-UHFFFAOYSA-K 0.000 description 9
- 239000007788 liquid Substances 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 235000017550 sodium carbonate Nutrition 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 159000000014 iron salts Chemical class 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229950008006 ferric maltol Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 150000002506 iron compounds Chemical class 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 3
- 239000002841 Lewis acid Substances 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 150000001449 anionic compounds Chemical class 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000000151 deposition Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910001412 inorganic anion Inorganic materials 0.000 description 3
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 3
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 3
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 3
- 150000007517 lewis acids Chemical class 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- OXXDGKNPRNPMLS-UHFFFAOYSA-N 2-Hydroxy-3-methyl-4H-pyran-4-one Natural products CC1=C(O)OC=CC1=O OXXDGKNPRNPMLS-UHFFFAOYSA-N 0.000 description 2
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 2
- NCQVIRXINIIOJT-UHFFFAOYSA-N 3,4-dihydroxypyran-2-one Chemical compound OC=1C=COC(=O)C=1O NCQVIRXINIIOJT-UHFFFAOYSA-N 0.000 description 2
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ZEGRKMXCOCRTCS-UHFFFAOYSA-N Poppy acid Chemical compound OC(=O)C1=CC(=O)C(O)=C(C(O)=O)O1 ZEGRKMXCOCRTCS-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000005591 charge neutralization Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Chemical compound CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- IDSXLJLXYMLSJM-UHFFFAOYSA-N morpholine;propane-1-sulfonic acid Chemical compound C1COCCN1.CCCS(O)(=O)=O IDSXLJLXYMLSJM-UHFFFAOYSA-N 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- FMOAICBJDCGMMD-UHFFFAOYSA-N 3-hydroxy-1h-pyridin-2-one;iron Chemical class [Fe].OC1=CC=CNC1=O FMOAICBJDCGMMD-UHFFFAOYSA-N 0.000 description 1
- FYFLKJJEBGDUEF-UHFFFAOYSA-N 5-hydroxypyran-2-one Chemical compound OC=1C=CC(=O)OC=1 FYFLKJJEBGDUEF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OOKCZXGEYPSNIM-UHFFFAOYSA-N CC1=CC(=O)C=C(O)O1 Chemical compound CC1=CC(=O)C=C(O)O1 OOKCZXGEYPSNIM-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000001734 carboxylic acid salts Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229940006199 ferric cation Drugs 0.000 description 1
- 229940044631 ferric chloride hexahydrate Drugs 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 150000004687 hexahydrates Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000006278 hypochromic anemia Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 1
- RUTXIHLAWFEWGM-UHFFFAOYSA-H iron(3+) sulfate Chemical compound [Fe+3].[Fe+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O RUTXIHLAWFEWGM-UHFFFAOYSA-H 0.000 description 1
- 229910000360 iron(III) sulfate Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- LIVNCPMCQTZXRZ-UHFFFAOYSA-N meconic acid Natural products CC(=O)C1=CC(=O)C(O)=C(C(C)=O)O1 LIVNCPMCQTZXRZ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical compound OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 150000004685 tetrahydrates Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
純粋なマルトールからのトリマルトールの調製
水溶液中の水和イオンとしての塩化第二鉄は、Kaが7×10−3の強いルイス酸であり、水溶液中の水和イオンとしての塩化第一鉄もKaが5×10−9の強いルイス酸である。第二鉄トリマルトールの合成のための出発材料として塩化鉄を使用する所望の範囲にわたって、水溶液中の塩化第二鉄は、1〜3の範囲のpH値を有し、塩化第一鉄は、3〜5の範囲のpH値を有する。また、市販の塩化鉄の溶液は、水酸化第二鉄種の析出を防止するために塩酸を添加することによって安定化されるため、約1のpHを有する。
マルトールを水酸化ナトリウムの水溶液に溶解させ、塩化第二鉄を添加して鉄マルトールを析出させた。
マルトールを炭酸ナトリウムの水溶液に溶解させ、塩化第二鉄を添加して鉄マルトールを析出させた。
マルトールを水に溶解させ、沸騰温度付近まで加熱し、塩化第二鉄または塩化第一鉄を添加して、第二鉄マルトールの1:1/1:2混合物を形成した。溶液を冷却させ、水酸化ナトリウムに溶解したマルトールに添加した。
必要なバッチサイズに応じて、塩化第二鉄を6〜7のpHの水中マルトール溶液に徐々に添加した。マルトールの溶解度は、60℃より高い温度まで加熱することによって10g/100mlまで大きく高められる。塩化第二鉄または塩化第一鉄を添加し、溶液のpHを監視し、pH>3を維持すると、主に第二鉄ジマルトール種が生成され、第二鉄トリマルトールが非常に少なくなる。pH3を超えると、水酸化第二鉄の生成が認められなかった。電荷中和をもたらすヒドロキシまたは塩化物を含む第二鉄モノマルトールおよびジマルトール種は、極めて溶解しやすく、30g/100mlを超える高濃度溶液が生成され得る。第二鉄トリマルトールの形成のための正確な化学量論組成を得るために、さらなるマルトールが必要であり、pHを7より高い値に補正する必要がある。
アルカリ溶液中のマルトールについては、以上に記載した。便利なことに、水酸化ナトリウム中の20%までのマルトール溶液は約11.6のpHを有するため、この溶液を段階1の第二鉄モノ/ジマルトール溶液と混合すると、紫外−可視分光分析法で測定した純度が高い濃い特徴的なワインレッド色の第二鉄トリマルトールの析出物が得られる。濾液から、GMP(優良製造プロセス)に適する生成物が得られる。このプロセスによって生成される塩化ナトリウムは、第二鉄トリマルトールよりはるかに高い35g/100mlの溶解度を有するため、上澄みに見いだされる。必要であれば、水で洗浄することによって、第二鉄トリマルトール中の少量の塩化ナトリウムを減少させることができる。
Claims (23)
- ヒドロキシピロンと非カルボン酸鉄塩とを水溶液中で反応させ、7超のpHを有する水溶液から鉄ヒドロキシピロン化合物を析出させる工程を含む鉄ヒドロキシピロン化合物の形成方法。
- 前記方法が有機溶媒の使用を含まないか、または水溶液の最終pHが7超、例えば8または9超である請求項1に記載の方法。
- 前記ヒドロキシピロンと非カルボン酸鉄塩とをアルカリ水溶液中で反応させる工程を含む請求項1または請求項2に記載の方法。
- 前記ヒドロキシピロンと非カルボン酸鉄塩とを40℃超または60℃超の温度で反応させる工程を含む請求項1から3のいずれか1項に記載の方法。
- 前記非カルボン酸鉄塩を、場合により固体または水溶液の形で、水溶液中のヒドロキシピロンに添加する請求項1から4のいずれか1項に記載の方法。
- 前記ヒドロキシピロンがアルカリ水溶液中にあり、それに対して非カルボン酸塩を添加するか、またはヒドロキシピロンを水溶液に添加し、溶液を加熱し、非カルボン酸塩を加熱された溶液に添加し、得られた該溶液を、ヒドロキシピロンを含むアルカリ水溶液と混合する請求項1から5のいずれか1項に記載の方法。
- 前記ヒドロキシピロンと非カルボン酸塩とを7未満の初期pHで反応させることによって鉄モノヒドロキシピロン、鉄ジヒドロキシピロンまたはそれらの混合物を形成し、および/またはさらなるヒドロキシピロン化合物を水溶液に添加し、および/またはpHを7超に高める請求項1から6のいずれか1項に記載の方法。
- 前記非カルボン酸鉄塩を、固体または水溶液の形でヒドロキシピロン水溶液に添加する請求項1から7のいずれか1項に記載の方法。
- 前記非カルボン酸鉄塩が、塩化第二鉄、硝酸第二鉄、塩化第一鉄、硫酸第一鉄およびそれらの混合物などの第一鉄塩または第二鉄塩から選択される請求項1から7のいずれか1項に記載の方法。
- 前記ヒドロキシピロンがヒドロキシ−4−ピロンである請求項1から8のいずれか1項に記載の方法。
- 前記ヒドロキシ−4−ピロンが、3−ヒドロキシ−4−ピロン、および環炭素原子に結合した水素原子の1個または複数個が1から6個の炭素原子を有する脂肪族炭化水素基によって置換されている3−ヒドロキシ−4−ピロンからなる群から選択される請求項9に記載の方法。
- 前記ヒドロキシピロンが、マルトール、エチルマルトールおよびそれらの混合物から選択される請求項1から11のいずれか1項に記載の方法。
- 前記鉄ヒドロキシピロン化合物が、第二鉄トリヒドロキシピロン、例えば第二鉄トリマルトールなどの鉄トリヒドロキシピロンである請求項1から11のいずれか1項に記載の方法。
- 前記水溶液が、全溶液の30%v/v超の量の水を含む請求項1から13のいずれか1項に記載の方法。
- 前記水溶液が、約10%w/vから約20%w/v、例えば約15%w/vの量のアルカリ金属水酸化物などの塩基を含む請求項1から14のいずれか1項に記載の方法。
- 前記鉄ヒドロキシピロン化合物を前記水溶液から析出して、析出物および水溶液を含む懸濁液を形成し、該析出物を該懸濁液から分離および回収し、場合により乾燥させる請求項1から15のいずれか1項に記載の方法。
- 請求項1から16のいずれか1項に記載の方法によって得られる鉄ヒドロキシピロン化合物。
- 鉄ヒドロキシピロン化合物と、水酸化鉄とを含む医薬組成物。
- 前記組成物が、マルトール、エチルマルトールおよびそれらの混合物などのヒドロキシピロン化合物をさらに含む請求項18に記載の組成物。
- 前記組成物が、例えば粉末、カプセルまたは錠剤などの固体の形である請求項18または請求項19に記載の組成物。
- 前記水酸化鉄が、前記組成物の重量に対して10重量%未満、例えば0.01から2重量%の量で前記組成物に存在する請求項18から20のいずれか1項に記載の組成物。
- 医薬品に使用される請求項18から21のいずれか1項に記載の組成物。
- 貧血の治療および/または予防に、あるいは被験者の血流中の鉄の量を増加させるために使用される請求項18から22のいずれか1項に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1101370.3 | 2011-01-27 | ||
GBGB1101370.3A GB201101370D0 (en) | 2011-01-27 | 2011-01-27 | Process |
PCT/GB2012/050160 WO2012101442A1 (en) | 2011-01-27 | 2012-01-26 | Process |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2014503579A true JP2014503579A (ja) | 2014-02-13 |
JP6055781B2 JP6055781B2 (ja) | 2016-12-27 |
Family
ID=43769665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013550951A Active JP6055781B2 (ja) | 2011-01-27 | 2012-01-26 | プロセス |
Country Status (14)
Country | Link |
---|---|
US (2) | US9096629B2 (ja) |
EP (2) | EP2668175B2 (ja) |
JP (1) | JP6055781B2 (ja) |
KR (1) | KR101925103B1 (ja) |
CN (1) | CN103443091B (ja) |
AU (1) | AU2012210337B2 (ja) |
BR (1) | BR112013018762A2 (ja) |
CA (1) | CA2824931C (ja) |
ES (2) | ES2627089T5 (ja) |
GB (1) | GB201101370D0 (ja) |
RU (1) | RU2621681C2 (ja) |
SG (1) | SG192153A1 (ja) |
WO (1) | WO2012101442A1 (ja) |
ZA (1) | ZA201305221B (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017508799A (ja) * | 2014-03-12 | 2017-03-30 | シールド ティーエックス (ユーケー) リミテッド | 組成物 |
JP2017535510A (ja) * | 2014-10-28 | 2017-11-30 | アイロン・セラピューティクス・ホールディングス・アーゲー | マルトール第二鉄の結晶形態 |
JP2018504392A (ja) * | 2015-01-09 | 2018-02-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | 小分子を用いた鉄欠乏生物における生理機能の回復 |
JP2019510772A (ja) * | 2016-03-31 | 2019-04-18 | シールド ティーエックス (ユーケー) リミテッド | 水酸化第一鉄からマルトール第二鉄組成物を生成するための方法 |
JP2019510776A (ja) * | 2016-03-31 | 2019-04-18 | シールド ティーエックス (ユーケー) リミテッド | 元素鉄からマルトール第二鉄組成物を生成するための方法 |
JP2019515893A (ja) * | 2016-03-31 | 2019-06-13 | シールド ティーエックス (ユーケー) リミテッド | 配位子修飾及び配位子コーティングされた水酸化第二鉄からマルトール第二鉄組成物を生成するための方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015204192B2 (en) * | 2014-01-06 | 2020-03-26 | Shield TX (UK) Limited | Dosage regimen of ferric trimaltol |
WO2015198304A1 (en) | 2014-06-22 | 2015-12-30 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
GB201418710D0 (en) | 2014-10-21 | 2014-12-03 | Iron Therapeutics Holdings Ag | Dosage regimen |
EA201892194A1 (ru) | 2016-03-31 | 2019-04-30 | Юнайтед Киндом Рисёрч Энд Инновейшн | Композиции комплекса трехвалентного железа с мальтолом для применения для лечения или предотвращения рака и опухолей |
IT202100018578A1 (it) | 2021-07-14 | 2023-01-14 | Indena Spa | Dispersione amorfa di maltolo ferrico e relativo processo di preparazione |
CN114113066B (zh) * | 2021-12-27 | 2023-09-29 | 西北农林科技大学 | 麦芽酚铁过氧化物模拟酶在检测过氧化氢和总抗氧化能力中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097627A1 (en) * | 2002-05-18 | 2003-11-27 | Vitra Pharmaceuticals Limited | Method of forming iron hydroxypyrone compounds |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54101445A (en) * | 1978-01-27 | 1979-08-10 | Sanei Kagaku Kogyo Kk | Perfume maltol preparation |
EP0107458B1 (en) | 1982-10-22 | 1987-07-29 | National Research Development Corporation | Pharmaceutical compositions |
USRE37534E1 (en) * | 1982-10-22 | 2002-01-29 | Btg International Limited | Pharmaceutical compositions |
GB8308055D0 (en) | 1983-03-24 | 1983-05-05 | Hider R C | Pharmaceutical compositions |
GB8410290D0 (en) | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
GB8410289D0 (en) * | 1984-04-19 | 1984-05-31 | Callingham B A | Pharmaceutical compositions |
ES2230564T3 (es) | 1995-06-10 | 2005-05-01 | Vitra Pharmaceuticals Ltd. | Compuestos ferricos, composiciones, metodos de fabricacion de estos y sus utilizacioneds. |
JP2000191516A (ja) * | 1998-10-23 | 2000-07-11 | Taisho Pharmaceut Co Ltd | 経口固形組成物 |
DE10041893A1 (de) * | 2000-08-25 | 2002-03-07 | Truetzschler Gmbh & Co Kg | Vorrichtung an einer Regulierstrecke zum direkten Ermitteln von Einstellwerten für den Reguliereinsatzpunkt |
US20030190355A1 (en) * | 2002-04-05 | 2003-10-09 | Hermelin Marc S. | Modified release minerals |
CN1408364A (zh) * | 2002-09-20 | 2003-04-09 | 单玉华 | 一类补铁剂干混悬剂的处方组成 |
CA2550699A1 (en) * | 2003-12-29 | 2005-07-21 | Alza Corporation, Inc. | Novel drug compositions and dosage forms of topiramate |
BRPI0515847A (pt) * | 2004-10-08 | 2008-08-12 | Unilever Nv | uso de um complexo de ferro, composição alimentìcia, gênero alimentìcio fortificado com ferro, composição de bebida, bebida fortificada com ferro, suplemento alimentar e composição farmacêutica |
GB0808835D0 (en) | 2008-05-15 | 2008-06-18 | Vitra Pharmaceuticals Ltd | Therapeutic compositions |
US8996104B2 (en) * | 2008-06-25 | 2015-03-31 | Fe3 Medical, Inc. | Patches and method for the transdermal delivery of a therapeutically effective amount of iron |
-
2011
- 2011-01-27 GB GBGB1101370.3A patent/GB201101370D0/en not_active Ceased
-
2012
- 2012-01-26 RU RU2013139544A patent/RU2621681C2/ru active
- 2012-01-26 JP JP2013550951A patent/JP6055781B2/ja active Active
- 2012-01-26 EP EP12708368.1A patent/EP2668175B2/en active Active
- 2012-01-26 WO PCT/GB2012/050160 patent/WO2012101442A1/en active Application Filing
- 2012-01-26 US US13/981,551 patent/US9096629B2/en active Active
- 2012-01-26 AU AU2012210337A patent/AU2012210337B2/en active Active
- 2012-01-26 KR KR1020137022561A patent/KR101925103B1/ko active IP Right Grant
- 2012-01-26 CA CA2824931A patent/CA2824931C/en active Active
- 2012-01-26 ES ES12708368T patent/ES2627089T5/es active Active
- 2012-01-26 CN CN201280006090.4A patent/CN103443091B/zh active Active
- 2012-01-26 EP EP17158230.7A patent/EP3192793B1/en active Active
- 2012-01-26 ES ES17158230T patent/ES2918004T3/es active Active
- 2012-01-26 SG SG2013056981A patent/SG192153A1/en unknown
- 2012-01-26 BR BR112013018762A patent/BR112013018762A2/pt not_active Application Discontinuation
-
2013
- 2013-07-11 ZA ZA2013/05221A patent/ZA201305221B/en unknown
-
2015
- 2015-06-25 US US14/750,462 patent/US20150320863A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097627A1 (en) * | 2002-05-18 | 2003-11-27 | Vitra Pharmaceuticals Limited | Method of forming iron hydroxypyrone compounds |
Non-Patent Citations (6)
Title |
---|
JPN6015036829; MORITA,H. et al: 'Synthesis and properties of tris(3-hydroxy-2-methyl-4-pyronato) complexes of chromium(III), manganes' Chemistry Letters No.4, 1975, p.339-342 * |
JPN6015036830; NURCHI,V.M. et al: 'Iron(III) and aluminum(III) complexes with hydroxypyrone ligands aimed to design kojic acid derivati' Journal of Inorganic Biochemistry Vol.104, No.5, 2010, p.560-569 * |
JPN6015036831; MUKHA,S.A. et al: 'Synthesis and properties of metal chelates based on natural gamma-pyrone maltol' Chemistry for sustainable development Vol.15, 2007, p.448-458 * |
JPN6015036832; AHMET,M.T. et al: 'A potential iron pharmaceutical composition for the treatment of iron-deficiency anemia. The crystal' Journal of the Chemical Society, Dalton Transactions No.5, 1988, p.1159-1163 * |
JPN6015036833; KAZMI,S.A. et al: 'Determination of redox potential and stability constant of Iron(III)-3-hydroxy-2-methyl-4-pyrone com' Journal of the Chemical Society of Pakistan Vol.30, No.6, 2008, p.824-828 * |
JPN6015036834; GERARD,C. et al: 'Iron(III) complexes of maltol (3-hydroxy-2-methyl-4-pyrone), including hydroxo-complexes, in an acid' Journal of Chemical Research, Synopses No.9, 1980, p.314 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2017508799A (ja) * | 2014-03-12 | 2017-03-30 | シールド ティーエックス (ユーケー) リミテッド | 組成物 |
JP2017535510A (ja) * | 2014-10-28 | 2017-11-30 | アイロン・セラピューティクス・ホールディングス・アーゲー | マルトール第二鉄の結晶形態 |
JP2018197268A (ja) * | 2014-10-28 | 2018-12-13 | シールド ティーエックス (ユーケー) リミテッド | マルトール第二鉄の結晶形態 |
JP2018504392A (ja) * | 2015-01-09 | 2018-02-15 | ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイThe Board Of Trustees Of The University Of Illinois | 小分子を用いた鉄欠乏生物における生理機能の回復 |
US11517540B2 (en) | 2015-01-09 | 2022-12-06 | The Board Of Trustees Of The University Of Illinois | Restoring physiology in iron-deficient organisms using small molecules |
JP2019510772A (ja) * | 2016-03-31 | 2019-04-18 | シールド ティーエックス (ユーケー) リミテッド | 水酸化第一鉄からマルトール第二鉄組成物を生成するための方法 |
JP2019510776A (ja) * | 2016-03-31 | 2019-04-18 | シールド ティーエックス (ユーケー) リミテッド | 元素鉄からマルトール第二鉄組成物を生成するための方法 |
JP2019515893A (ja) * | 2016-03-31 | 2019-06-13 | シールド ティーエックス (ユーケー) リミテッド | 配位子修飾及び配位子コーティングされた水酸化第二鉄からマルトール第二鉄組成物を生成するための方法 |
US11155529B2 (en) | 2016-03-31 | 2021-10-26 | Shield TX (UK) Limited | Methods for producing ferric maltol compositions from elemental iron |
JP7033544B2 (ja) | 2016-03-31 | 2022-03-10 | シールド ティーエックス (ユーケー) リミテッド | 水酸化第一鉄からマルトール第二鉄組成物を生成するための方法 |
JP7033545B2 (ja) | 2016-03-31 | 2022-03-10 | シールド ティーエックス (ユーケー) リミテッド | 配位子修飾及び配位子コーティングされた水酸化第二鉄からマルトール第二鉄組成物を生成するための方法 |
JP7033546B2 (ja) | 2016-03-31 | 2022-03-10 | シールド ティーエックス (ユーケー) リミテッド | 元素鉄からマルトール第二鉄組成物を生成するための方法 |
Also Published As
Publication number | Publication date |
---|---|
ZA201305221B (en) | 2021-06-30 |
US20150320863A1 (en) | 2015-11-12 |
RU2621681C2 (ru) | 2017-06-07 |
US9096629B2 (en) | 2015-08-04 |
ES2627089T5 (es) | 2021-09-27 |
ES2627089T3 (es) | 2017-07-26 |
US20140088064A1 (en) | 2014-03-27 |
CA2824931A1 (en) | 2012-08-02 |
EP3192793B1 (en) | 2022-03-16 |
EP3192793A1 (en) | 2017-07-19 |
BR112013018762A2 (pt) | 2016-10-25 |
RU2013139544A (ru) | 2015-03-10 |
SG192153A1 (en) | 2013-08-30 |
AU2012210337A1 (en) | 2013-03-21 |
AU2012210337B2 (en) | 2014-07-17 |
GB201101370D0 (en) | 2011-03-09 |
EP2668175B1 (en) | 2017-03-08 |
EP2668175B2 (en) | 2021-01-06 |
CA2824931C (en) | 2019-08-06 |
CN103443091B (zh) | 2017-05-10 |
EP2668175A1 (en) | 2013-12-04 |
WO2012101442A1 (en) | 2012-08-02 |
JP6055781B2 (ja) | 2016-12-27 |
KR101925103B1 (ko) | 2018-12-05 |
CN103443091A (zh) | 2013-12-11 |
ES2918004T3 (es) | 2022-07-13 |
KR20140022377A (ko) | 2014-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6055781B2 (ja) | プロセス | |
JP7030093B2 (ja) | オキサチアジン様化合物を作製する方法 | |
TW200843760A (en) | Fluorinated derivatives of deferiprone | |
US7459569B2 (en) | Method of forming iron hydroxypyrone compounds | |
JP6678711B2 (ja) | マルトール第二鉄の結晶形態 | |
JP5662719B2 (ja) | 2−[[[2−[(ヒドロキシアセチル)アミノ]−4−ピリジニル]メチル]チオ]−n−[4−(トリフルオロメトキシ)フェニル]−3−ピリジンカルボキサミドのベンゼンスルホン酸塩、その結晶、その結晶多形およびそれらの製造方法 | |
WO1999051588A1 (fr) | Derives d'acide quinolonecarboxylique ou sels de ceux-ci | |
JPWO2020096041A1 (ja) | (S)−2−アミノ−3−{4−[(5−アミノ−2−フェニルベンゾ[d]オキサゾール−7−イル)メトキシ]−3,5−ジクロロフェニル}プロパン酸・1塩酸塩、その1水和物、およびその結晶とその製造方法 | |
CN116355017A (zh) | 用于抗病毒的新型核苷类逆转录酶抑制剂 | |
KR100971486B1 (ko) | 아데포비어 다이피복실 말론산염 및 이를 포함하는 약제학적 조성물 | |
EP2340020A1 (en) | Manganese and cobalt complexes, their preparation and use | |
JPH04356476A (ja) | アスコルビン酸誘導体,その製造法および用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20131120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20131120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150123 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150903 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150909 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151209 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160706 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160913 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161013 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161109 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6055781 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |